NeoGenomics, Inc. Common Stock

NEO US64049M2098

💰
Capitalization
Small-cap

NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.

Annual Performance 1
2021 2022 2023 2024 2025
-38% -74% 78% 3% 0%
Annual Insiders Turnover, USD 2

1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);

Insider Activity
📊
Transactions
25
🙍
Insiders
9
Person Price Shares Total Published Completed
Zook Anthony P.
CEO
5.58
USD
17,900
Bought
99,954
USD
06/08/2025 06/08/2025
Sherman Jeffrey Scott
CFO
5.62
USD
20,000
Bought
112,322
USD
06/08/2025 06/08/2025
Kelly Michael Aaron
7.60
USD
5,000
Bought
38,000
USD
27/05/2025 27/05/2025
Kelly Michael Aaron
7.60
USD
5,000
Bought
38,000
USD
27/05/2025 27/05/2025
Kelly Michael Aaron
7.60
USD
5,000
Bought
38,000
USD
27/05/2025 27/05/2025
Stone Warren
PR
8.58
USD
5,700
Bought
48,895
USD
11/05/2025 12/05/2025
Tetrault Lynn A.
8.14
USD
7,000
Bought
56,974
USD
09/05/2025 09/05/2025
Kanovsky Stephen M
7.78
USD
4,000
Bought
31,124
USD
07/05/2025 07/05/2025
Kanovsky Stephen M
7.78
USD
4,000
Bought
31,124
USD
07/05/2025 07/05/2025
Zook Anthony P.
CEO
7.88
USD
18,900
Bought
148,919
USD
06/05/2025 06/05/2025

Integrated EOD Stock Data and Insider Transactions Chart

Sign in or subscribe to include NeoGenomics, Inc. Common Stock to your watchlist and receive automatic alerts for upcoming transactions.

The visibility of insider buy and sell transactions on this chart should not be the sole factor in your decision to buy or sell a particular stock. Always consider the following dynamic reports for a broader understanding of stock market activities:

 

Historical Performance
1M 3M 6M 1Y 3Y 5Y All Time
26% -7% 7% 1% -57% 52% 118%
Last 52W Low 52W High All-Time Low All-Time High β
9.03 4.84 10.27 4.84 10.27
Company Insiders
Person / Entity Transactions Turnover, USD Average, USD First Last
Sherman Jeffrey Scott 3 412,530.00 137,510.00 02/05/2025 06/08/2025
Zook Anthony P. 3 397,791.14 132,597.05 06/05/2025 06/08/2025
Olivo Alicia C 7 359,427.68 51,346.81 17/11/2023 15/11/2024
Tetrault Lynn A. 2 154,553.09 77,276.54 04/03/2024 09/05/2025
Perez David Brian 2 152,600.00 76,300.00 05/05/2025 05/05/2025
Kelly Michael Aaron 3 114,000.00 38,000.00 27/05/2025 27/05/2025
Gunn Neil 2 69,954.90 34,977.45 05/05/2025 05/05/2025
Kanovsky Stephen M 2 62,248.80 31,124.40 07/05/2025 07/05/2025
Stone Warren 1 48,894.60 48,894.60 12/05/2025 12/05/2025

Insiders marked in yellow represent long-term insiders. These are individuals who have engaged in transactions for over 3 years and have conducted at least 10 transactions or reached a cumulative turnover of $1M USD. When examining transaction clusters, we prioritize those conducted by long-term insiders for analysis.

Connected Companies 3
Name ISIN Ticker
Rhythm Pharmaceuticals, Inc. US76243J1051 RYTM

3 the firms where the current insiders have executed transactions.

Stock Advanced Metrics
Delta Correlation subscribe 🔒
Upper Bound of Standardized Transaction Amount (ubsta), USD 4 subscribe 🔒

4 represents the maximum expected transaction amount for a company's insiders, calculated based on historical data. It provides insight into the typical range of insider transaction amounts and helps in identifying unusually large transactions.

5 a proprietary metric reflecting the consistency of insider trading behavior within a company. A higher discipline index suggests more regular and predictable insider transactions.